Downregulation of serum epidermal growth factor in patients with inflammatory bowel disease. Is there a link with mucosal damage?

Growth Factors

Volumn 28, Issue 6, 2010, Pages 461-466

  Oikonomou, Konstantinos A ^a   Kapsoritakis, Andreas N ^a   Kapsoritaki, Anastasia I ^b   Manolakis, Anastassios C ^a   Tsiopoulos, Fotios D ^a   Germenis, Anastassios E ^b   Potamianos, Spiros P ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b University of Thessaly School of Medicine   (Greece)

Author keywords

Crohn's disease; Epidermal growth factor; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; FEMALE; GASTROINTESTINAL TRACT; GREECE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED;

EID: 78650579933     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2010.527967     Document Type: Article

References (29)

1. Beck PL, Podolsky DK. 1999. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 5:44-60.
2. Best WR, Becktel JM, Singleton JW, Kern F, Jr. 1976. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 70:439-444.
3. Bulut K, Felderbauer P, Hoeck K, Schmidt WE, Hoffmann P. 2008. Increased duodenal expression of transforming growth factoralpha and epidermal growth factor during experimental colitis in rats. Eur J Gastroenterol Hepatol 20:989-994.
4. Chowdhury A, Fukuda R, Fukumoto S. 1996. Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients. J Gastroenterol 31:353-360. (Pubitemid 26181790)
5. Cohen S. 1962. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237:1555-1562.
6. Deban L, Correale C, Vetrano S, et al. 2008. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: A Jack of all trades. Am J Pathol 172:1457-1466. (Pubitemid 351793339)
7. Dignass AU, Baumgart DC, Sturm A. 2004. Review article: The aetiopathogenesis of inflammatory bowel disease-immunology and repair mechanisms. Aliment Pharmacol Ther 20(Suppl 4): 9-17. (Pubitemid 39319241)
8. Farrell RJ. 2003. Epidermal growth factor for ulcerative colitis. N Engl J Med 349:395-397. (Pubitemid 36886247)
9. Hormi K, Cadiot G, Kermorgant S, Dessirier V, Le Romancer M, Lewin MJ, Mignon M, Lehy T. 2000. Transforming growth factor-alpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease. Growth Factors 18:79-91.
10. Ido A, Numata M, Kodama M, Tsubouchi H. 2005. Mucosal repair and growth factors: Recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol 40:925-931. (Pubitemid 41662515)
11. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. 2004. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 49:1752-1757. Kasselberg AG, Orth DN, Gray ME, Stahlman MT. 1985. (Pubitemid 40228532)
12. Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues. J Histochem Cytochem 33:315-322. (Pubitemid 15122789)
13. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. 1998. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395:713-716. (Pubitemid 28475970)
14. Konturek JW, Bielanski W, Konturek SJ, Bogdal J, Oleksy J. 1989. Distribution and release of epidermal growth factor in man. Gut 30:1194-1200. (Pubitemid 19255426)
15. Lennard-Jones JE. 1989. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170:2-6; discussion 16-19.
16. Ma L, Wang WP, Chow JY, Yuen ST, Cho CH. 2000. Reduction of EGF is associated with the delay of ulcer healing by cigarette smoking. Am J Physiol Gastrointest Liver Physiol 278:G10-17. (Pubitemid 30108062)
17. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA,Werb Z, Derynck R. 1995. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337-341.
18. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. 1997. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530. (Pubitemid 27527914)
19. Playford RJ. 1995. Peptides and gastrointestinal mucosal integrity. Gut 37:595-597.
20. Rachmilewitz D. 1989. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 298:82-86. (Pubitemid 19032930)
21. Schultz G, Rotatori DS, Clark W. 1991. EGF and TGF-alpha in wound healing and repair. J Cell Biochem 45:346-352.
22. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. 2003. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349:350-357. (Pubitemid 36886241)
23. Sipos F, Molnár B, Zágoni T, Berczi L, Tulassay Z. 2005. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: Ulcerative colitis shows specific p53- and EGFR expression alterations. Dis Colon Rectum 48:775-786. (Pubitemid 40880726)
24. Sturm A, Dignass AU. 2008. Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol 14:348-353. (Pubitemid 351320844)
25. Sullivan PB, Lewindon PJ, Cheng C, Lenehan PF, Kuo BS, Haskins JR, Goodlad RA, Wright NA, de la Iglesia FA. 2007. Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis. J Pediatr Surg 42:462-9. Erratum in: J Pediatr Surg 42:1470. (Pubitemid 46335706)
26. Svrcek M, Cosnes J, Tiret E, Bennis M, Parc Y, Fléjou JF. 2007. Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer. Virchows Arch 450:243-244. (Pubitemid 46295226)
27. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M. 1995. Growth factors: New 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl 210:15-18.
28. Tarnawski AS, Jones MK. 1998. The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: Involvement of EGF-R signal transduction pathways. J Clin Gastroenterol 27(Suppl 1): S12-S20.
29. Walmsley RS, Ayres RC, Pounder RE, et al. 1998. A simple clinical colitis activity index. Gut 43:29-32.